Search
Tagraxofusp
go.drugbank.com/drugs/DB14731ApprovedInvestigationalIt is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in _Escherichia coli_.
Synonyms: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptorAluminum sesquichlorohydrate
go.drugbank.com/drugs/DB11108ApprovedAluminum sesquichlorohydrate is an aluminum salt used as an antiperspirant agent, cosmetic astringent and deodorant agent. It works by physically blocking eccrine sweat gland ducts .
Products: Power Stick XJ Intensity, Power Stick XJ Coolblast XtremeCalcium gluconate
go.drugbank.com/drugs/DB11126ApprovedInvestigationalVet approvedHydrochloric acid and/or sodium hydroxide may have been added for pH adjustment (6.0 to 8.2). … Each 10 mL of the injection provides 93 mg elemental calcium (Ca++) equivalent to 1 g of calcium gluconate.
Mixtures: CALPİNES 225 MG/10 ML + 572 MG/10 ML ENJEKSİYONLUK ÇÖZELTİ, 5 ADET, CALCIO AL 10% AMPOLLASProducts: Calcium Gluconate Inj 100mg/ml, Calcium Gluconate 10% Inj 100mg/mlNivolumab
go.drugbank.com/drugs/DB09035ApprovedInvestigationalNivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1).
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitorsProducts: OPDIVO CONCENTRATE FOR SOLUTION FOR INFUSION 10 MG/ML, Opdivo 10mg/ml, Concentrate for solution for infusionButylscopolamine
go.drugbank.com/drugs/DB09300ApprovedInvestigationalVet approvedButylscopolamine is a peripherally acting antimuscarinic, anticholinergic agent. It is used to treat pain and discomfort caused by abdominal cramps, menstrual cramps, or other spasmodic activity in the digestive system. It is also effect...
Mixtures: DIPIRONA 2.5 G + HIOSCINA 20 MG/5 ML SOLUCION INYECTABLE, N-BUTIL BROMURO DE HIOSCINA20MG + DIPIRONA 2500 MG/5 MLProducts: TIMOPTOL-XE, BUSTON INJECTION 20MG/MLCosibelimab
go.drugbank.com/drugs/DB15770ApprovedInvestigationalCosibelimab is a human IgG1 lambda monoclonal antibody directed against programmed death ligand-1 (PD-L1). … On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the
Synonyms: anti-Pd-l1 monoclonal antibody CK-301, IMMUNOGLOBULIN G1-LAMBDA, ANTI-(HOMO SAPIENS PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1, CD274 ANTIGEN))HUMAN MONOCLONAL ANTIBODY.GAMMA.1 HEAVY CHAIN (1-450) (HOMO SAPIENS VH (IGHV1-69*01 (94%) (IGHD)-IGHJ1Rosuvastatin
go.drugbank.com/drugs/DB01098ApprovedInvestigationalvascular event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsSynonyms: (3R,5S,6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acidFondaparinux
go.drugbank.com/drugs/DB00569ApprovedInvestigationalFondaparinux potentiates the neutralizing action of ATIII on activated Factor X 300-fold. … knee surgery); to prevent VTE in patients undergoing abdominal surgery who are are at high risk of thromboembolic complications; in the treatment of deep vein thrombosis (DVT) and pumonary embolism (PE
Categories: Factor Xa Inhibitors, Indirect factor Xa inhibitorsProducts: ARIXTRA (12.5 MG/ML), ARIXTRA 2.5 MG / 0.5 MLPenpulimab
go.drugbank.com/drugs/DB16747ApprovedInvestigationalPenpulimab is a humanized monoclonal IgG1 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). … The use of an IgG1 backbone - as opposed to an IgG4 backbone as is typical in other anti-PD-1 antibodies like [nivolumab] - is intended to reduce the risk of immune-related adverse events.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsMoxifloxacin
go.drugbank.com/drugs/DB00218ApprovedInvestigationalMoxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for ...
Mixtures: Dex-Moxi PF, DexMoxiKetor PFCategories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors